Galapagos | GLPG - Ebitda

Stock Price
30.04
Daily Change
1.64 5.77%
Monthly
3.80%
Yearly
19.21%
Q1 Forecast
27.85

Galapagos reported EUR-158.71M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
argenx SE USD 288.02M 84.53M Jun/2025
AstraZeneca USD 5.23B 272M Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
Genmab DKK 477M 101M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
GRIFOLS EUR 347.24M 58.35M Jun/2025
Hikma Pharmaceutical USD 369M 84M Dec/2024
Incyte USD 414.5M 92.42M Dec/2025
Merck EUR 1.46B 45M Jun/2025
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novartis USD 5.88B 290M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
UCB EUR 1.03B 334M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025